@article {Tariqbcr2015213577, author = {Hassan Tariq and Bibi Ayesha and Karen Weidenheim and Giovanni Franchin}, title = {Etanercept-induced myositis: do we have to stop it? A surprising outcome}, volume = {2016}, elocation-id = {bcr2015213577}, year = {2016}, doi = {10.1136/bcr-2015-213577}, publisher = {BMJ Publishing Group}, abstract = {We discuss a case of a 47-year-old man who presented with progressive proximal muscle weakness of the upper and lower extremities and unstable gait. He had been on etanercept for 6 months for severe psoriasis and psoriatic arthritis with good control of his disease. Serum creatine kinase (CK) level was found to be 5666 U/L and muscle biopsy showed a marked inflammatory myopathic process likely secondary to etanercept. He was started on high-dose steroids and advised to discontinue etanercept. Despite our recommendation, he never stopped using etanercept due to fear of a psoriasis flare. Three months later, he had significant improvement of clinical symptoms, normalised serum CK levels and discontinued prednisone.}, URL = {https://casereports.bmj.com/content/2016/bcr-2015-213577}, eprint = {https://casereports.bmj.com/content/2016/bcr-2015-213577.full.pdf}, journal = {Case Reports} }